A Great Deal More Funding for the Development of Partial Reprogramming Therapies

The medical biotechnology and pharmaceutical investment market was always very risk averse, giving rise to the valley of death between preclinical seed funding and early clinical stage funding; there are all too few investors willing to fund companies to move from late preclinical stage to early clinical stage. They would rather let promising companies die...

Raccontata dafightaging.org